Table 2.
Hyperprolactinemia in children and adolescents with autism spectrum disorders receiving risperidone
| n (total 147) | Hyperprolactinemia (n=66), n (%) | P-value | |
|---|---|---|---|
| Sex | 0.001a | ||
| Male | 127 | 64 (50.39) | |
| Female | 20 | 2 (10.00) | |
| Age-group | 0.638b | ||
| Children (3–12 years) | 114 | 50 (43.86) | |
| Adolescents (13–19 years) | 33 | 16 (48.48) | |
| Drug regimen | 0.468b | ||
| Single risperidone | 85 | 36 (42.35) | |
| Concomitant therapy | 62 | 30 (48.39) | |
| Dose of risperidone treatment | 0.004a | ||
| Low dose | 15 | 4 (26.67) | |
| Recommended dose | 97 | 38 (39.18) | |
| High dose | 35 | 24 (68.57) | |
Notes:
a
Fisher’s extract test
b
χ2 test.